Sarcomeric protein isoform transitions in cardiac muscle: A journey to heart failure  by Yin, Zhiyong et al.
Biochimica et Biophysica Acta 1852 (2015) 47–52
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReviewSarcomeric protein isoform transitions in cardiac muscle: A journey to
heart failureZhiyong Yin a,b, Jun Ren c, Wei Guo a,c,⁎
a Animal Science, College of Agriculture and Natural Resources, University of WY, Laramie WY82071, USA
b Department of Cardiology, Xi Jing Hospital, Fourth Military Medical University, Xi'an 710032, PR China
c Center for Cardiovascular Research and Alternative Medicine, College of Health Science, University of WY, Laramie WY82071, USA⁎ Corresponding author at: 1000 E. University Ave., La
307 766 3429; fax: +1 307 766 2355.
E-mail address: wguo3@uwyo.edu (W. Guo).
http://dx.doi.org/10.1016/j.bbadis.2014.11.003
0925-4439/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 16 September 2014
Received in revised form 27 October 2014
Accepted 4 November 2014
Available online 8 November 2014
Keywords:
Protein isoform transition
Sarcomere proteins
Alternative splicing
Heart failureSarcomeric protein isoforms are mainly governed by alternative promoter-driven expression, distinct gene
expression, gene mutation and alternative mRNA splicing. The transitions of sarcomeric proteins have been
implicated to play a role in the onset and development of human heart failure. In this mini-review, we summa-
rized isoform transitions of several most widely examined sarcomeric proteins includingmyosin, actin, troponin,
tropomyosin, titin and myosin binding protein-C, and the consequence of these abnormal isoform transitions.
Even though the isoform transitions of sarcomeric proteins have been described in individual sarcomeric protein
reviews, no concise summary of these results has been presented previously. This review is intended to ﬁll this
gap and discuss possible future perspectives.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Heart failure (HF) has been amajor public health focuswith an esca-
lating health threat [1]. A failing heart is characterized by unfavorable
alterations in myocardial contraction (systolic dysfunction) and/or
impaired ability of ventricular ﬁlling (diastolic dysfunction). Heart
failure is a complex clinical syndrome attributed to a number of factors
such as changes in cardiac structure, for example, dilation and hypertro-
phy, abnormal energy metabolism, intracellular calcium handling
defects, and sarcomeric dysfunction. Recent studies revealed that
alterations in sarcomeric function play a cardinal role in the develop-
ment of heart failure [2,3].
Sarcomeric function is determined by post-translational modiﬁca-
tions and by the levels of multiple isoforms of sarcomeric proteins.
Themost abundant sarcomeric proteins are contractile proteins/myoﬁl-
ament proteins (myosin and actin), regulatory proteins (troponins and
tropomyosin) and cytoskeletal proteins (myosin binding protein C and
titin). All of these proteins are located in the sarcomere, and take up
approximately 80% of the myoﬁbril mass. In one sarcomere unit, N-
terminus of titin anchors to Z-disk and C-terminus of it attaches to M-
line, which spans half sarcomere from the Z-disk to center of the
sarcomere. Titin is attached to both actin and myosin and is anchored
to the Z-disk (Z-line). Myosin is in the center of the sarcomere. Actin
is cross-linked in the Z-lines and overlaps with myosin (Fig. 1A) [4,5].ramie WY82071, USA. Tel.: +1Fig. 1B is a diagram of the thin ﬁlament and thick ﬁlament in cardiac
muscle indicating the four major components: myosin, actin, tropomy-
osin (Tm) and troponin complex (TnT, TnC and TnI). During muscle
contraction, binding of calcium ions to TnC triggers a conformational
rearrangement in the troponin complex, and then the movement of
tropomyosin exposes a space for myosin binding on actin, which allows
cross-bridge formation driven by the energy provided from ATP hydro-
lysis [6,7]. The impairment of these proteins will result in the dysfunc-
tion of muscle contraction, which is associated with transition to heart
failure. Recent evidence depicted that aberrant expression levels and
transition of sarcomeric protein isoforms are associatedwith sarcomeric
dysfunction. The current review describes isoform alterations of the
major sarcomeric proteins and the resulting functional consequences
in cardiac muscle.
2. Myoﬁlament proteins
Myoﬁlament proteins make up the bulk of the sarcomere. Actin and
myosin are the major contractile proteins of the thin and thick
ﬁlaments, respectively. They are responsible for force generation during
muscle contraction.
2.1. Myosin
Themyosinmotormolecule generates force andmotion by coupling
its ATPase activity to its cyclic interaction with actin. Myosin consists of
twomyosin heavy chains (MHCs) and two essential and two regulatory
myosin light chains (MLCs) [8]. Mammalian cardiac myosin heavy
Fig. 1. The location and arrangement of themost abundant proteins in the cardiac sarcomere, the basic contractile unit. A, Titin anchors each half sarcomere from the Z-line to the M-line;
theN-terminal I-band region of titin is bound to actin that is located to Z-line at its N-terminus and attached tomyosin at its C-terminus; the C-terminal A-band segment of titin is attached
to the thickﬁlament viamultiple binding sites formyosin andmyosin binding protein C (C-protein); B, The thinﬁlament is composed of actin, tropomyosin, and the troponin complex (Tn-
T, Tn-C, and Tn-I). The thick ﬁlament is composed of myosin and C protein; during muscle contraction, calcium binding to Tn-C induces a conformational rearrangement in Tn-C, causing
the Tn-C:Tn-I association to strengthen while at the same time weakening the Tn-I:Tn-T association; movement of tropomyosin exposes a myosin binding site on actin allowing cross-
bridge formation driven by the energy from ATP hydrolysis.
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distinct genes [9]. In rodent hearts, the α-MHC is the major isoform of
the ventricular myocardium (~90%) [10], while the β-isoform is
predominant in human ventricularmyocardium (~95%) [11]. Themam-
malian α-isoform is associated with higher actomyosin ATPase activity
than the β-isoform, therefore, hearts expressing α-isoform possess
more rapid contractile velocity than hearts expressing β-isoform. The
β-isoform imparts greater economy in force generation because the
tension time integral for force per cross-bridge cycle is greater [12].
Cardiac MHC isoform expression is species-dependent, develop-
mentally controlled, and sensitive to hormonal perturbations and
cardiovascular stress [13,14]. The shift or transition between cardiac
MHC isoforms might play an important role in cardiac function. The
transition of cardiac MHC isoforms has been observed in hyperthyroid
compared with euthyroid rats, which the transition is from the slow
β-isoform to the fast α-isoform [15]. The transition from the slow β-
isoform to the fast α-isoform has also been found in human failing
myocardium [3,10], and thyroid depletion, aging, cardiomyopathy,
and pressure overload have been shown to increase β-isoform [16].
Additionally, down-regulation of α-isoform and up-regulation of β-
isoform occur during experimental induction of heart failure in
mammalian myocardium that normally expresses predominantly α-
isoform [17]. A regional shift of cardiacMHC isoformshas been observed
in human and rat ventricular tissues, with the fast α-isoform exhibiting
a higher expression in the subepicardial than in the subendocardial
layer [18]. This regional transition of MHC isoforms is consistent with
contraction duration and the shorter action potential in the sub-
epicardium compared with sub-endocardium. Recent reports have
demonstrated that a slight shift of isoforms will have a signiﬁcantinﬂuence on cardiomyocyte contractility [19]. In contrast to human ven-
tricular tissues, atria human tissues contain ~80% of α-isoform [20]. In
atrial ﬁbrillation, expression of β-isoform is increased almost two-fold
[21], and in failing right and left ventricles, α-isoform was expressed
in a signiﬁcant lower level [20]. Overall, aberrant isoform switching
between α-isoform and β-isoform may likely occur in diseased
human atria and ventricular myocardium.
The isoform shift also occurs in MLCs within the heart. Particularly,
isoform alterations have been reported for MLC-1 (essential MLC)
both in atrial and ventricular myocardium. Essential MLC (MLC-1) has
two isoforms: a ventricular form (VLC-1) and an atrial form (ALC-1)
[22]. The entire heart muscle expresses ALC-1 during fetal and early
life and is subsequently replaced by VLC-1. Patients with hypertrophic
obstructive cardiomyopathy in ventricles express a higher ratio of
ALC-1 to VLC-1 [23]. However, the isoform ratios between ALC-1 and
VLC-1 display much larger individual differences in ischemic and
idiopathic cardiomyopathy (IDCM) [22,23]. In addition, cardiac function
can be beneﬁted by the addition of the N-terminal region of MLC-1 via
certain mechanisms that the N-terminus of MLC-1 peptide directly
inﬂuences interaction of proteins and exerts an inotropic effect via
cooperative mechanisms, which activate the entire thin ﬁlament [22].
Therefore, up-regulation of the N-terminal fragment of MLC-1
isoform might provide a therapeutic approach to strengthen cardiac
performance.
2.2. Actin
Actin is essential for a very wide range of cell functions. Mammalian
actin isoforms are highly conserved and ubiquitously found in
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encode six different actin isoforms. Four isoforms, α-cardiac actin, α-
skeletal actin, α-smooth actin, and γ-smooth actin, are present respec-
tively in cardiac, skeletal, and smooth muscles, while the other two
isoforms, named β-cyto actin and γ-cyto actin, are ubiquitously
expressed in tissues and cells. These isoforms are extremely similar to
each other, with exclusive small variations in the protein sequence
[24]. The four muscle actins are restricted to tissues with high tonic
activity such as striated heart muscle, skeletal muscle and smoothmus-
cle [25]. The α-cardiac actin is the predominant isoform in adult hearts,
accounting for approximately 80% of total actin in both human ventric-
ular and atrial samples. Theα-skeletal actin is found to be about 20% in
adult myocardium [24]. The early expression of the α-smooth isoform
in the fetal human heart and its replacement by α-skeletal actin
suggests that these proteins may play distinct roles in myocyte growth
and development. The subtle changes of these isoform ratios may be
causing important differences in contractility. Cardiac contractility has
been proved to be affected by the expression ratio of α-skeletal actin
and α-cardiac actin [24]. Moreover, there is evidence to indicate that
ectopic expression of γ-smooth actin and decreased α-cardiac actin
expression reduce cardiac contractility [26]. Combined with other
results, theymay explainwhy largemammals such as humans normally
have much higher levels of α-skeletal actin in their hearts than small
mammals such as rats and mice [27]. In an animal model, α-cardiac
actin deﬁciency leads to lethality at embryonic or perinatal stage with
profound disarray of cardiac myoﬁbrils [28]. α-skeletal actin deﬁcient
mice appear healthy at birth, however, all of these mice die with weak
muscles by 9 days of age [29]. α-Smooth actin deﬁcient mice appear
normal and are viable but have functional impairment in blood pressure
regulation and vascular contractility [30]. The transgenic animalmodels
indicated that over-expression of γ-smooth actin only partially rescued
mice lacking α-cardiac actin, suggesting that γ-smooth actin and α-
cardiac actin eachmake divergent contributions to cardiomyocyte func-
tion [28]. Up-regulation ofα-cardiac actin inα-skeletal actin knockouts
fully rescued the lethality andmuscle function defects, which suggests a
potential treatment for heart failure associated with reduced α-skeletal
actin [29]. For the more detailed discussion on actin isoforms the
readers are referred to some recent reviews [25,31].
3. Regulatory proteins
Muscle contractility is controlled by sarcoplasmic Ca2+, which acts
on the receptor molecule troponin in thin ﬁlaments [7]. Ca2+ is bound
to troponin C that in turn binds to troponin I, releasing it from its
inhibitory site on actin. Second, the TnT binding to Tm and the overlap
of Tm from adjacent thin ﬁlament regulatory units allow coupling and
propagation of Tm motion along the thin ﬁlament. Finally, cross-
bridge binding contributes to activation by stabilizing the Tm/Tn unit
in an activated position. The extent of this coupling, or cooperative
activation, varies with the composition of the regulatory protein
isoforms [7].
3.1. Tropomyosin
Tropomyosin is formed as a homodimer or heterodimer of two α-
helical chains arranged as a coiled coil. The composition of tropomyosin
isoforms in actin ﬁlaments plays a crucial role in functional regulation of
actin ﬁlaments in either muscle or non-muscle cells. This family is often
divided into two groups as muscle tropomyosin isoforms and non-
muscle tropomyosin isoforms [32]. Tropomyosin isoforms are involved
in the regulation of interactions between actin and myosin in the
muscle sarcomere and play a pivotal role in modulating the kinetics of
activation of muscle contraction [33]. In humans, tropomyosin isoforms
are encoded by four highly conserved genes (TPM1, TPM2, TPM3 and
TPM4). Each of them can produce multiple isoforms through the use
of different promoters, alternative splicing, and different sites of poly(A) addition signals [34]. The principal tropomyosin isoforms found in
human striated muscles are α-tropomyosin and κ-tropomyosin from
TPM1 gene, β-tropomyosin from TPM2 gene, and γ-tropomyosin tran-
scribed from TPM3 gene. In adult human hearts, β to α-tropomyosin
ratio is about 1:4.8, while in large animals such as beef, pig and sheep
this ratio is present at approximately 1:4, and in small animals like
rabbit, rat and dog only the α-isoform is expressed in the heart [35].
There are very few reports that the isoform transition of Tm is asso-
ciated with human heart disease. To the best of our knowledge, one
studyhas reported that failing heart ventricularmuscle expresses exclu-
sively α-tropomyosin isoform [36], and one recent study showed that
increased expression of κ-tropomyosin isoform has been found in the
hearts of patients with chronic dilated cardiomyopathy (DCM) [37,38].
However, in the rodent model, the α-tropomyosin isoform knockout
mice showed an embryonic lethal phenotype, but in the heterozygotes,
the knockout mice indicated normal phenotype as compared to control
mice, suggesting that the levels of the protein are regulated at the trans-
lational level [39]. In a transgenic mouse model, the overexpression of
β-tropomyosin isoform to 57.8 % of total heart tropomyosin demon-
strates altered diastolic function with reduced rates of contraction and
relaxation of isolated myocytes [40]. If the overexpression of β-
tropomyosin isoform is over 75% of total heart tropomyosin, the mice
die 10 to 14 days after birth and show severe cardiac abnormalities
and thrombus formation [41]. In the mouse model overexpressing γ-
tropomyosin isoform, the mice show increased heart rate and reduced
Ca2+ sensitivity [42]. These data imply that tropomyosin isoform
transition or composition alteration potentially affects cardiac function
in humans.
3.2. Troponins
Troponin complex acts as a calcium-sensitive regulator of striated
muscle contraction and consists of three regulatory proteins: the
calcium binding protein troponin C (TnC), the inhibitory protein tropo-
nin I (TnI), and the tropomyosin-binding protein troponin T (TnT) [43].
TnC is encoded by at least two genes (TNNC1 and TNNC2) found in
the genomes of higher animals. TNNC2 encodes the fast skeletal isoform
(fsTnC), and TNNC1 encodes a single TnC isoform that is expressed in
slow muscle and in heart muscle. It is referred to as ssTnC in slow
muscle and as cTnC in the heart [44]. In the heart muscle of higher
vertebrates, only ssTnC/cTnC isoform has been expressed in both devel-
oping and adult hearts. So far, there have been no reports of troponin C
isoform transitions during myocardial development or pathological
adaptations [45].
TnI has three isoforms (ssTnI isoform in the slow skeletal muscle,
fsTnI isoform in the fast skeletal muscle and cTnI isoform in the cardiac
muscle) encoded by TNNI1, TNNI2 and TNNI3 respectively [46]. TnI is
developmentally regulated in rat heart with co-expression of the ssTnI
and cTnI in fetal heart. With development, the ratio of the ssTnI to
cTnI is decreased, and the ssTnI is non-detectable in adult heart [46].
The developmental change of TnI isoforms in the human heart is similar
to that in the rat heart. Each individual gene coded for the three TnI
isoforms has no mRNA alternative splicing. The adult heart only
expresses cTnI and doesn't undergo isoform switching to skeletal
forms even under pathological conditions such as ischemic heart failure,
dilated cardiomyopathy, and end-stage heart failure [47]. However,
over-expression of slow TnI in cardiac muscle of adult transgenic mice
impaired cardiomyocyte relaxation and diastolic cardiac function due
to increased Ca2+ sensitivity [48].
TnT also has three muscle type-speciﬁc isoforms: the slow skeletal
muscle TnT (ssTnT), the fast skeletalmuscle TnT (fsTnT) and the cardiac
muscle TnT (cTnT). These three isoforms are encoded by three genes:
TNNT1, TNNT3 and TNNT2 separately [49]. Each TnT gene undergoes
alternative splicing and generates multiple isoforms [45,49]. In human
heart, there are at least four isoforms of cTnT (cTnT1, cTnT2, cTnT3
and cTnT4). The four isoforms of human cTnT are expressed in a
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isoforms are expressed in the fetal heart, with a very low expression
level of cTnT2. During the perinatal heart development, the expression
level of cTnT1 decreases, and the expression of cTnT3 increases and
appears as the only isoform in the normal adult heart. The cTnT4
isoform is also expressed in the fetal heart, but not in the adult heart;
however, it is re-expressed in the failing adult heart [50]. Abnormal
cTnT isoform expression has been linked to heart disease. The exon4
skipped isoform was increased in failing human heart [50], diabetic rat
heart [51], and familial hypertrophic cardiomyopathy human hearts
[52]. A shift in cardiac TnT splicing toward the fetal pattern appears in
a rabbit model with mild cardiac hypertrophy [53]. In a guinea pig
model with induced ventricular hypertrophy, four distinct TnT isoforms
underwent changes in the relative proportions of the different isoforms
during hypertrophy [54]. The skipping of conserved exon8 has been
found in turkeys with inherited dilated cardiomyopathy and heart
failure [55]. Aberrant skipping of exon7 appeared in cTnT of dog, pig
and cat, indicating the high risk of dilated cardiomyopathy [56]. Overex-
pression of exon7-excluded cTnT isoform in the transgenic mouse heart
leads to impaired systolic function [57]. Re-expression of the embryonic
exon5 in adult heart was detected in dilated cardiomyopathy dogs [56].
The heterogeneity of TnT isoforms or co-presence of different TnT
isoforms reduces cardiac performance by desynchronizing the calcium
activation of thin ﬁlaments [58]. Previous studies have suggested that
cardiac muscle contractile functions in adult mice were signiﬁcantly
impaired by co-existence of the endogenous cardiac TnT and
overexpressed non-mutant fast TnT [59]. Further studies demonstrated
that overexpression of one or more functionally distinct cardiac TnT
isoforms in mice developed lower left ventricular pressure, decreased
stroke volume, and produced slower contractile and relaxation veloci-
ties when compared to wild-type controls. These studies further imply
that co-expression of functionally distinct cardiac TnT isoforms
facilitates adverse inﬂuences on cardiac function in adult ventricular
muscle due to desynchronized actin ﬁlament activation [58].
4. Sarcomeric cytoskeletal proteins
Cytoskeletal proteins contribute to cell shape,mechanical resistance,
and morphological integrity of cardiomyocytes. The sarcomeric
cytoskeletal proteins are referred to as titin, myosin binding protein C
(C-protein), α-actinin, myomesin, M-protein, etc. [60]. In this review,
we will only cover the isoform transitions of titin and myosin binding
protein-C (C-protein) in cardiac disease.
4.1. Titin
Titin is a giant muscle protein expressed in vertebrate striated
muscle. It is the third most abundant sarcomeric protein with an aver-
age about 10% of myoﬁbril mass. It is the largest protein known to
date, and is also known as connectin [61,62]. Titin spans the entire
half of the sarcomere from Z-line to M-line, and two titin molecules
form a continuous ﬁlament along the whole length of the sarcomere
by overlapping at the M-line [4,5] (Fig. 1A). The three elements of titin
in the extensible I-band region are key determinants of myocardial
passive tension and play a critical role in elastic recoil of the cardiac
myocytes and contribute to diastolic function during left ventricular
(LV) ﬁlling phase [63]. These three elements are 1) tandem Ig segments
consisting of serially-linked immunoglobulin (Ig)-like domains, 2) the
spring-like PEVK segment (with high percentages of proline, glutamic
acid, valine, and lysine), and 3) the N2B element with its extensible
unique sequence (N2B-Us) [4,63,64].
Titin is encoded by a single gene and the alternative splicing of this
single gene results in distinct isoform classes [64]. There are three
major isoform classes in mammalian cardiac muscle [63]. These cardiac
titin are the smaller, stiffer, adult N2B (3.0 MDa), the larger, more
compliant adult N2BA (3.2–3.7 MDa) and the largest fetal cardiac titin(FCT: ~3.7 MDa) [4,64–66]. Alteration of the cardiac titin isoform
expression ratios has recently been linked to cardiac disease. In animal
models, a canine tachycardia-inducedmodel of dilated cardiomyopathy
(DCM) indicates increased N2B titin after two to four weeks of pacing
[67]. Another study of spontaneously hypertensive rat model (SHR)
also showed a reduced ratio of N2BA/N2B titin in response to pressure
overload, consistent with elevated passive tension of heart [68]. In
human patients, left ventricle biopsies from patients with diastolic
heart failure (HF) had a reduced N2BA/N2B titin [69]. Chronically ische-
mic LVs of coronary-artery-disease (CAD) patients with congestive
heart failure (HF) had nearly 50% N2BA titin (compared to total titin
(N2BA + N2B)) while approximately 30% N2BA was found in the LVs
of control donor patients [70]. Analysis of explanted nonischaemic
human DCM hearts again demonstrated increased proportions of
N2BA/N2B [71,72]. Upregulation of compliant isoforms has also been
found in patients with heart failure with preserved ejection fraction
(HFpEF), a group accounting for about half of all HF cases and character-
ized by increased diastolic stiffness [73,74]. Recently, a muscle-speciﬁc
splicing factor, RNA binding motif 20 (Rbm20), has been found to
regulate titin alternative splicing [75]. The Rbm20 deﬁcient rats express
largest titin isoform (~3.83 MDa), a most compliant titin isoform, and
develop dilated cardiomyopathy [75–77], which has been conﬁrmed
by a most recent study with the Rbm20 knockout mice [78]. RBM20
mutations in patients with severe dilated cardiomyopathy also lead to
the expression of the larger, compliant fetal cardiac titin isoform [75].
4.2. Myosin binding protein-C (C-protein)
Myosin binding protein-C (MyBP-C) is a thick ﬁlament-associated
protein localized to the cross-bridge containing C zones of striated
muscle sarcomeres, where it binds to myosin and titin. Titin fulﬁlls the
role of a molecular ruler [55], and MyBP-C plays a role as a spatially
deﬁned regulatory protein [56–59]. Myosin, MyBP-C, and titin form a
stable ternary complex where MyBP-C is arranged regularly in 9 of the
11 thick-ﬁlament stripes [79].
Three isoforms of MyBP-C are known to exist in adult striated
muscle. Skeletal muscle expresses at least two isoforms of MyBP-C.
The fsMyBP-C is the fast skeletal isoform encoded by gene MYBPC2 in
human. The ssMyBP-C is the slow form in skeletal muscle encoded by
MYBPC1 in human [80]. Human cardiac MyBP-C (cMyBP-C) is encoded
by gene MYBPC3 [56]. The fast and slow skeletal muscle isoforms can
be co-expressed in the same sarcomeres [81] and can coexist in variable
ratios leading to diverse arrangements of the characteristic sarcomere
stripes [82], so skeletal muscle has a great potential to adapt to alter-
ations in MyBP-C isoforms by modiﬁcation of co-expression ratios in a
ﬂexible way. However, the cardiac isoform is expressed only in cardiac
muscle throughout development, and the cardiac isoform of MyBP-C
cannot be trans-complemented by skeletal MyBP-Cs [83]. So far, to the
best of our knowledge, there have been no reports of isoform transitions
or altered ratios of skeletal and cardiac MyBP-C in failing heart. Never-
theless, mutation-caused truncated cardiac MyBP-C isoforms have
been a cause of hypertrophic cardiomyopathy, which is beyond the
scope of this review. More details can be obtained from recent reviews
regarding mutations in cardiac myosin binding protein-C [84–88].
5. Conclusion and future perspective
The sarcomeric proteins myosin, actin, troponin, tropomyosin and
titin show isoform switching during development. Some protein
isoforms are due to distinct gene expression (myosin, actin, MyBPC,
tropomyosin, TnI and TnC); others arise from alternative splicing
(titin, tropomyosin and TnT). Aberrant sarcomeric protein isoform tran-
sitions and sarcomeric gene alternative splicing involved in the heart
failure have been only partially identiﬁed. The isoform transitions
associated with heart failure are mostly embryonic-like gene re-
expression. The mechanism(s) of embryonic-like gene re-expression
51Z. Yin et al. / Biochimica et Biophysica Acta 1852 (2015) 47–52may be attributed to isoform transitions with development. Therefore,
the developmental mechanisms of isoform alterations of sarcomeric
proteins are essential to decipher the embryonic-like gene re-
expression in failing heart. However, the developmental mechanism
of sarcomeric protein isoform transition is still poorly understood.
Nevertheless, the understanding of protein isoform transitions in nor-
mal and failing heart is progressing rapidly. In the near future, we
believe that manipulation of gene alternative splicing or ratios of
isoform transitions of sarcomeric proteins may provide an encouraging
strategy for the treatment of chronic heart failure.
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